SGP
SpyGlass Pharma, Inc.
SGP
Closed
$32.24
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical, which engages in the development of treatment paradigm for patients living with chronic eye conditions. The company is headquartered in Aliso Viejo, California and currently employs 65 full-time employees. The firm is focused on developing and commercializing long-term, drug delivery solutions for patients suffering from ophthalmic diseases. Its lead product candidate is SpyGlass Drug Delivery Platform with bimatoprost, which is designed to deliver three years of bimotic anti-inflammatory therapy to targeted tissues in the eye.
Key stats
Open
$32.21
Volume
125.37K
Market cap
$1.09B
Prev. close
$32.51
Impl / hst vl
-
Open interest
$0.00
$31.75
Day’s Range
$32.92
$17.06
52W Range
$33.84
Valuation
38
Valuation score
Overvalued
P/E
-
P/S
-
P/B
4.73
Current ratio
25.06
Debt / Equity
-0.96
ROE
-
Gross margin
-
Income growth
43.75%
FCF growth
17.94
Analysts estimates
Consensus rating
Strong buy
The average rating from top 5 analysts indicates that stock may significantly outperform the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$42.51
The top 7 analysts forecasts that 12-month price may increase by 31.85%, with a low of $25.30 and a high of $65.10
$25.30
Low
$42.51
Avg
$65.10
High
Current price
Earnings
Q2 ‘26 revenue
$0.00
Q2 ‘26 net income
-$19.86M
Revenue
Net income
Previous EPS
-$0.69
Estimate EPS
-$0.52
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply